Answers are grounded in this paper and cite their sources.
Cost-effectiveness findings for adjuvant trastuzumab in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer vary across settings. We synthesized evidence using incremental net benefit (INB) and examined heterogeneity by country income group. We systematically reviewed full economic evaluations published from 1998 to March 2025 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed. Scopus, and EBSCOhost were searched. Costs were standardized to 2024 purchasing power parity-adjusted international dollars (Int$). INB was pooled at a reference willingness-to-pay threshold of Int$100,000 per quality-adjusted life-year using random-effects models with restricted maximum likelihood estimation and Knapp–Hartung adjustment. Eighteen studies were included. Pooled INB was negative and imprecise in high-income settings (12 studies; approximately −Int$38,000), with the 95% confidence interval spanning zero. In middle-income settings (six studies), pooled INB was positive (approximately Int$90,000), with the confidence interval above zero. Heterogeneity was substantial (I2 ≈ 99%), and findings depended on the threshold. No low-income countries were represented. Estimates suggested favorable economic value in the included middle-income settings at the reference threshold. They do not establish affordability or generalizability across countries. Funding decisions require local assessment of economic value, budgets, and treatment capacity. PROSPERO, CRD42024623623 Trastuzumab is a medicine used with other treatments for early breast cancer that produces high levels of a protein called HER2. It can reduce cancer recurrence and improve survival, but its cost can put pressure on patients and healthcare budgets. We reviewed 18 economic studies published between 2007 and 2024. They compared treatment including trastuzumab with treatment without it. We adjusted costs to a common year and accounted for differences in purchasing power, then combined the additional costs and health benefits to compare economic value. Twelve studies were from high-income countries. The other six were from five middle-income countries: Brazil, Colombia, Iran, the Philippines, and Vietnam. No studies represented low-income countries or sub-Saharan Africa. At the common comparison threshold, the combined results suggested better economic value in the included middle-income settings, while results in high-income settings remained uncertain. However, the studies differed substantially in prices, assumptions, and treatment pathways. These findings cannot be applied to all countries. The comparison threshold does not reflect what every healthcare system can afford or should spend. Treatment that appears to offer good value at this threshold may still be unaffordable locally. The estimated benefits depend on access to HER2 testing, surgery, chemotherapy, other treatments, and monitoring. Introducing trastuzumab alone cannot ensure these benefits. Late diagnosis may also limit the number of patients eligible for early-stage treatment. Funding decisions therefore need local evidence on costs, benefits, budgets, and treatment capacity. They should also consider earlier diagnosis, patient access, and other services competing for limited resources.
No takes yet. Share an insight, caveat, or question.
Majam et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: